Truelove and Witts published the first placebo-controlled, randomised clinical trial in inflammatory bowel disease (IBD), which showed the superiority of cortisone for the treatment of acute ...

The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

What’s Crohn’s and what are the symptoms? - Crohn’s disease is a lifelong condition which affects more than 200,000 people in ...

7, 2023 — Millions of Americans have inflammatory bowel disease (IBD), which occurs in one of two forms: Crohn's disease or ulcerative colitis. Though the two have similar symptoms, they require ...

Johnson & Johnson (NYSE: JNJ) has announced the FDA‘s approval of TREMFYA® (guselkumab) for adults with moderately to ...

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly ...

US FDA approves Johnson & Johnson’s Tremfya for adults with moderately to severely active ulcerative colitis: Horsham, Pennsylvania Friday, September 13, 2024, 12:00 Hrs [IST] J ...

The prevalence of inflammatory bowel disease (IBD) in the United States is approximately 0.9% of the general population, with ulcerative colitis (UC) affecting 0.4% and Crohn’s disease (CD) affecting ...

Approval of the dual-acting interleukin (IL)-23 inhibitor in ulcerative colitis was based on findings from QUASAR, an ongoing ...

Tremfya’s ulcerative colitis approval on Wednesday comes as Johnson & Johnson’s blockbuster immunotherapy Stelara continues to face growing competition from biosimilars.

Increasing incidences and prevalence of ulcerative colitis, demand for drugs has been increased across the globe. The North America region emerged as the largest market for the ulcerative colitis drug ...